N-acetylglutamate Synthase: Structure, Function & Defects
N-乙酰谷氨酸合成酶:结构、功能
基本信息
- 批准号:8035600
- 负责人:
- 金额:$ 9.98万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-04-01 至 2012-03-31
- 项目状态:已结题
- 来源:
- 关键词:Acetyl Coenzyme AAddressAffectAllosteric SiteAmino Acid SubstitutionAmino AcidsAnabolismArginineAwardBacteriaBehavior TherapyBindingBiochemicalBiochemistryBiologicalBiologyBrain InjuriesCarbamyl PhosphateCatalysisCessation of lifeCitrullineClinicalClinical TrialsCloningCoenzyme ACommitComputer Systems DevelopmentCrystallizationDNA FootprintDataDefectDevelopmental DisabilitiesDiagnosisDisciplineDiseaseEngineeringEnzyme InhibitionEnzymesEscherichia coliEvolutionFunctional disorderGene ProteinsGenesGenetic TranscriptionGenotypeGlutamatesGonorrheaHealthHepaticHumanHyperammonemiaHypersensitivityInheritedIntestinesKnowledgeLaboratoriesLeadLearningLigandsLigaseLiverMammalsMapsMessenger RNAMethodsMitochondrial MatrixMolecularMusMutationN acetyl L glutamateNeisseria gonorrhoeaeOrganOrganismPhenotypePhylogenetic AnalysisPhylogenyPhysiologicalPhysiologyPlantsPlayPrimer ExtensionProductionPropertyProtein KinaseProteinsProteobacteriaRaceRecombinant ProteinsRecombinantsRefractoryRegulationReportingReverse Transcriptase Polymerase Chain ReactionRoleSiteSmall IntestinesStructural ModelsStructureSurfaceSystemTetraodontidaeTissuesTranscription Initiation SiteTranscriptional RegulationUreaVertebratesX-Ray CrystallographyXanthomonasXanthomonas campestrisXylellaZebrafishbasechromatin immunoprecipitationcofactordensityelectron densityexpression cloningfascinatefungushepatic ureagenesishuman NAT7 proteinimprovedinsightinterestmicroorganismmutantprotein foldingprotein structureprotein structure functionresearch studystructural biologythree dimensional structurevalproate
项目摘要
DESCRIPTION (provided by applicant):
N-acetylglutamate synthase (NAGS) is an enzyme that produces the cognate cofactor N-acetylglutamate (NAG), an essential allosteric activator of the first and rate limiting enzyme of ureagenesis (CPS I) in mammals, and the first committed substrate for arginine biosynthesis in microorganisms. Our cloning and expression of the mouse and human NAGS genes and many other NAGS genes from various species, makes it now possible to gain structure/function insights into this interesting protein. We found in a number of proteobacteria species (X. campestris, M. maris, O. alexandrii, X. axonopodis, and X. fastidiosa Dixon) a gene for a bifunctional NAGS/NAGK that is similar to mammalian NAGS and for which we have obtained protein crystals. Recently, we obtained a high quality density map which will lead to the determination of the first three-dimensional structure of NAGS (from N. gonorrhoeae). Since NAGS is a likely regulator of ureagenesis and its function is allosterically affected by arginine, it is now possible to understand the mechanism(s) of the arginine effect and to compare the regulation of NAGS in hepatic vs. intestinal, tissues. The deficiency of NAG in inherited NAGS deficiency, organic acidemias and valproate treatment causes hyperammonemia that frequently leads to brain damage, developmental disabilities and death. Better understanding of the NAG/NAGS system will improve the diagnosis and treatment of these conditions. The specific aims of this project are 1) To solve the liganded and unliganded structures of NAGS and characterize mechanisms for catalysis and the effect of arginine; 2) To characterize the biochemical properties of NAGS proteins across phyla, focusing on the effect of arginine on structure and function; 3) To differentiate regulatory mechanisms that are specific to liver ureagenesis by characterizing and comparing the regulation of NAGS expression in liver and intestine; 4) To determine the functional effects of naturally-occurring mutations that cause inherited NAGS deficiency. Biochemical, crystallographic and molecular methods will be employed to gain an in depth understanding of the structural biology, biochemistry, pathophysiology, genotype/phenotype correlations of the NAGS genes and proteins in the context of evolutionary development of this system. After the first three- dimensional structure of NAGS has been solved, other structures of refractory NAGS proteins will become available. This will lead to constructing a structural model of mammalian NAGS, deriving at a catalytic mechanism, determining the mechanism of arginine effect, and the effects of mutations causing NAGS dysfunction and hyperammonemia.
描述(由申请人提供):
N-乙酰谷氨酸合酶 (NAGS) 是一种产生同源辅因子 N-乙酰谷氨酸 (NAG) 的酶,NAG 是哺乳动物尿素生成第一个限速酶 (CPS I) 的必需变构激活剂,也是精氨酸生物合成的第一个关键底物在微生物中。我们对小鼠和人类 NAGS 基因以及来自不同物种的许多其他 NAGS 基因进行克隆和表达,现在可以深入了解这种有趣的蛋白质的结构/功能。我们在许多变形菌物种(X. Campestris、M. maris、O. alexandrii、X. axonopodis 和 X. fastidiosa Dixon)中发现了一个双功能 NAGS/NAGK 基因,该基因与哺乳动物 NAGS 相似,并且我们有得到蛋白质晶体。最近,我们获得了高质量的密度图,这将有助于确定 NAGS(来自淋病奈瑟菌)的第一个三维结构。由于 NAGS 可能是尿素生成的调节剂,并且其功能受到精氨酸的变构影响,因此现在可以了解精氨酸效应的机制并比较 NAGS 在肝脏组织和肠道组织中的调节。遗传性 NAGS 缺乏、有机酸血症和丙戊酸治疗中 NAG 的缺乏会导致高氨血症,常常导致脑损伤、发育障碍和死亡。更好地了解 NAG/NAGS 系统将改善这些疾病的诊断和治疗。该项目的具体目标是 1) 解决 NAGS 的配体和非配体结构,并表征催化机制和精氨酸的作用; 2) 表征跨门NAGS蛋白的生化特性,重点关注精氨酸对结构和功能的影响; 3)通过表征和比较肝脏和肠道中NAGS表达的调节来区分肝脏尿素生成特有的调节机制; 4) 确定导致遗传性 NAGS 缺陷的自然发生突变的功能影响。将采用生物化学、晶体学和分子方法来深入了解 NAGS 基因和蛋白质在该系统进化发展背景下的结构生物学、生物化学、病理生理学、基因型/表型相关性。在解决了 NAGS 的第一个三维结构之后,难处理的 NAGS 蛋白的其他结构将变得可用。这将导致构建哺乳动物 NAGS 的结构模型,推导催化机制,确定精氨酸作用的机制,以及导致 NAGS 功能障碍和高氨血症的突变的影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mendel Tuchman其他文献
Mendel Tuchman的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mendel Tuchman', 18)}}的其他基金
Overall Adminstration of Rare Diseases Clinical Research Consortia (RDCRC)
罕见病临床研究联盟(RDCRC)的总体管理
- 批准号:
8916167 - 财政年份:2015
- 资助金额:
$ 9.98万 - 项目类别:
Pilot/Demonstration Clinical Research Projects Program
试点/示范临床研究项目计划
- 批准号:
8916164 - 财政年份:2015
- 资助金额:
$ 9.98万 - 项目类别:
N-CARBAMYLGLUTAMATE (CARBAGLU) IN THE TREATMENT OF HYPERAMMONEMIA
N-氨甲酰谷氨酸(CARBAGLU)治疗高氨血症
- 批准号:
8167358 - 财政年份:2010
- 资助金额:
$ 9.98万 - 项目类别:
N-carbamylglutamate in the treatment of hyperammonemia
N-氨甲酰谷氨酸治疗高氨血症
- 批准号:
8061384 - 财政年份:2010
- 资助金额:
$ 9.98万 - 项目类别:
N-carbamylglutamate in the treatment of hyperammonemia
N-氨甲酰谷氨酸治疗高氨血症
- 批准号:
7848468 - 财政年份:2009
- 资助金额:
$ 9.98万 - 项目类别:
N-acetylglutamate Synthase: Structure, Function & Defects
N-乙酰谷氨酸合成酶:结构、功能
- 批准号:
7809804 - 财政年份:2009
- 资助金额:
$ 9.98万 - 项目类别:
N-carbamylglutamate in the treatment of hyperammonemia
N-氨甲酰谷氨酸治疗高氨血症
- 批准号:
8440307 - 财政年份:2008
- 资助金额:
$ 9.98万 - 项目类别:
N-carbamylglutamate in the treatment of hyperammonemia
N-氨甲酰谷氨酸治疗高氨血症
- 批准号:
8254226 - 财政年份:2008
- 资助金额:
$ 9.98万 - 项目类别:
N-carbamylglutamate in the treatment of hyperammonemia
N-氨甲酰谷氨酸治疗高氨血症
- 批准号:
8613497 - 财政年份:2008
- 资助金额:
$ 9.98万 - 项目类别:
N-carbamylglutamate in the treatment of hyperammonemia
N-氨甲酰谷氨酸治疗高氨血症
- 批准号:
7667880 - 财政年份:2008
- 资助金额:
$ 9.98万 - 项目类别:
相似国自然基金
本体驱动的地址数据空间语义建模与地址匹配方法
- 批准号:41901325
- 批准年份:2019
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
时空序列驱动的神经形态视觉目标识别算法研究
- 批准号:61906126
- 批准年份:2019
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
针对内存攻击对象的内存安全防御技术研究
- 批准号:61802432
- 批准年份:2018
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
大容量固态硬盘地址映射表优化设计与访存优化研究
- 批准号:61802133
- 批准年份:2018
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
IP地址驱动的多径路由及流量传输控制研究
- 批准号:61872252
- 批准年份:2018
- 资助金额:64.0 万元
- 项目类别:面上项目
相似海外基金
Metabolism and Epigenetic Regulation are Couples in Transdifferentiation and Vascular Regeneration
代谢和表观遗传调控是转分化和血管再生的结合体
- 批准号:
10905167 - 财政年份:2023
- 资助金额:
$ 9.98万 - 项目类别:
Spatial Acetyl-CoA metabolism as a regulator of Hallmarks of Aging
空间乙酰辅酶A代谢作为衰老标志的调节剂
- 批准号:
10901039 - 财政年份:2023
- 资助金额:
$ 9.98万 - 项目类别:
Elucidating the role of hepatic mTORC2 as a key regulator of carbohydrate metabolism in non-alcoholic fatty liver disease
阐明肝脏 mTORC2 作为碳水化合物代谢关键调节因子在非酒精性脂肪肝中的作用
- 批准号:
10387520 - 财政年份:2022
- 资助金额:
$ 9.98万 - 项目类别:
Elucidating the role of hepatic mTORC2 as a key regulator of carbohydrate metabolism in non-alcoholic fatty liver disease
阐明肝脏 mTORC2 作为碳水化合物代谢关键调节因子在非酒精性脂肪肝中的作用
- 批准号:
10548816 - 财政年份:2022
- 资助金额:
$ 9.98万 - 项目类别:
Engineering of a mouse model of choline acetycholinesterase deficients using CRISPR/Cas9 gene editing
使用 CRISPR/Cas9 基因编辑构建胆碱乙酰胆碱酯酶缺陷小鼠模型
- 批准号:
10511979 - 财政年份:2022
- 资助金额:
$ 9.98万 - 项目类别: